Targeting lactate metabolism by FX11, a small-molecule inhibitor of LDHA, markedly inhibited MYC-driven lymphoma progression without prominent side effects in mice.104 However, homozygous LDHA mutation in germline did not inhibit either initiation or progression of MYC-induced B cell lymphoma, raising concerns on the feasibility of targeting LDHA as MYC-selective therapeutics. The gene discussed is LDHA; the disease is B-cell non-Hodgkin lymphoma.